Pluristem (PSTI) Q1/11 Results
PSTI had no revenues while R&D net of participation of the OCS (government re-imbursement) and other grants was $1.54M. This increase is attributed to the increase in stock-based compensation expenses, salaries and lab materials expenses due to the increase in the R&D activity. G&A expense was $1.15M which increased due to an increase in stock based compensation expenses. Financial income was $86K. As of Q1/11, total current assets were $45.6M and total current liabilities were $1.9M. PSTI finances operations from existing cash, funds from grants from the OCS.
- Cash and cash equivalents as of 3/31/11 was $44.86M.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.